How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,108 results for

Urine Occult Blood

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Urine Occult Blood

Urine Occult Blood Urine Occult Blood Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Urine Occult Blood Urine Occult Blood Aka: Urine (...) Occult Blood , Urine Dipstick Blood II. Interpretation: Normal Negative III. Interpretation: Positive (Urine Dipstick with blood) Dipstick blood must be confirmed with microscopic exam See for confirmatory exam Diagnosis of : 3 RBCs/hpf IV. Causes: False positive occult blood on Urine Dipstick Dehydration Non-urinary tract blood source (e.g. ) Alkalotic urine (pH >9) V. Causes: False negative occult blood on Urine Dipstick supplementation Increased 5.0 or less Images: Related links to external sites

2018 FP Notebook

2. Hematuria as a Marker of Occult Urinary Tract Cancer: Advice for High-Value Care From the American College of Physicians

, A. Qaseem. Analysis and interpretation of the data: M. Nielsen, A. Qaseem. Drafting of the article: M. Nielsen, A. Qaseem. Critical revision of the article for important intellectual content: M. Nielsen, A. Qaseem. Final approval of the article: M. Nielsen, A. Qaseem. Statistical expertise: A. Qaseem. Obtaining of funding: A. Qaseem. Administrative, technical, or logistic support: A. Qaseem. Collection and assembly of data: M. Nielsen. Abstract Background: The presence of blood in the urine (...) and procedures. However, the magnitude of the risk for underlying cancer varies greatly ( ), and the quality of evidence informing practice creates uncertainty. Hematuria occasionally has a dramatic presentation as grossly visible blood in the urine. Symptomatic gross hematuria with associated flank pain or renal colic is the classic presentation of urinary stone disease, whereas painless gross hematuria has a stronger association with cancer. Any episode of gross hematuria in an adult warrants consideration

2016 American College of Physicians

3. Urine Occult Blood

Urine Occult Blood Urine Occult Blood Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Urine Occult Blood Urine Occult Blood Aka: Urine (...) Occult Blood , Urine Dipstick Blood II. Interpretation: Normal Negative III. Interpretation: Positive (Urine Dipstick with blood) Dipstick blood must be confirmed with microscopic exam See for confirmatory exam Diagnosis of : 3 RBCs/hpf IV. Causes: False positive occult blood on Urine Dipstick Dehydration Non-urinary tract blood source (e.g. ) Alkalotic urine (pH >9) V. Causes: False negative occult blood on Urine Dipstick supplementation Increased 5.0 or less Images: Related links to external sites

2015 FP Notebook

4. Evidence-Based Screening Recommendations for Occult Cancers in the Setting of Newly Diagnosed Extramammary Paget Disease. (PubMed)

for an underlying malignancy, 17 distant, noncontiguous malignancies were identified in 15 patients (11.4%), with prostate (n=5), urinary tract (n=5), and breast (n=2) malignancies found most frequently. Most malignancies were identified by urine cytology, mammography, and prostate-specific antigen blood test. Of all patients, 37 (23.0%) had an underlying contiguous malignancy identified by pathology.All patients diagnosed with EMPD should undergo cancer screening. At minimum, evaluation should include age (...) -appropriate screening and the addition of urine cytology, mammography, and prostate-specific antigen blood test-if not already performed-may be of particular use. An algorithm for evaluation of patients with newly diagnosed EMPD is proposed.Copyright © 2018 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.

2018 Mayo Clinic Proceedings

5. Hematuria as a Marker of Occult Urinary Tract Cancer: Advice for High-Value Care From the American College of Physicians. (PubMed)

Hematuria as a Marker of Occult Urinary Tract Cancer: Advice for High-Value Care From the American College of Physicians. The presence of blood in the urine, or hematuria, is a common finding in clinical practice and can sometimes be a sign of occult cancer. This article describes the clinical epidemiology of hematuria and the current state of practice and science in this context and provides suggestions for clinicians evaluating patients with hematuria.A narrative review of available clinical (...) antiplatelet or anticoagulant therapy.Clinicians should not obtain urinary cytology or other urine-based molecular markers for bladder cancer detection in the initial evaluation of hematuria.

Full Text available with Trip Pro

2016 Annals of Internal Medicine

6. The Role of Occult Cardiac Amyloid in the Elderly With Aortic Stenosis.

. Other: Baseline assessment Baseline assessment will include clinical history, Quality of Life Questionnaire (EQ-5D/SF-12), a 6-minute-walk test, blood sampling for haematocrit, renal function, biomarkers (NT-pro-BNP and troponin), and biobanking (also for AL exclusions if scanning positive), a urine sample for biobanking (also for AL exclusions if scanning positive), as well as tests performed as the routine pre-operative work-up (clinical electrocardiogram, blood pressure to estimate global LV (...) -12), a 6-minute-walk test, blood sampling for haematocrit, renal function, biomarkers (NT-pro-BNP and troponin), and biobanking (also for AL exclusions if scanning positive), a urine sample for biobanking (also for AL exclusions if scanning positive), as well as tests performed as the routine pre-operative work-up (clinical electrocardiogram, blood pressure to estimate global LV afterload, valvulo-arterial impedance). Procedure: Transthoracic echocardiography Patients will undergo a clinical

2017 Clinical Trials

7. Using Fluorescence Angiography to Detect Occult Shock

: The purpose of this study is to determine if fluorescence angiography can detect occult shock (hypoperfusion). Condition or disease Intervention/treatment Hypoperfusion Device: skin perfusion image Detailed Description: Hypoperfusion may be multifactorial, due to hemorrhage, shock or other disease processes resulting in either capillary leak into the interstitium or profound vasodilatation. Currently, diagnosis of hypoperfusion depends on indirect markers of perfusion such as lactate, blood pressure (...) Using Fluorescence Angiography to Detect Occult Shock Using Fluorescence Angiography to Detect Occult Shock - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Using Fluorescence Angiography to Detect Occult

2016 Clinical Trials

8. Blood & Clots Series: How do you choose an anticoagulant for stroke prevention in atrial fibrillation?

Blood & Clots Series: How do you choose an anticoagulant for stroke prevention in atrial fibrillation? Blood & Clots Series: How do you choose an anticoagulant for stroke prevention in atrial fibrillation? - CanadiEM Blood & Clots Series: How do you choose an anticoagulant for stroke prevention in atrial fibrillation? In , by Kerstin de Wit October 23, 2018 All the content from the Blood & Clots series can be found . CanMEDS Roles addressed : Expert, health advocate, communicator Case (...) by prescription of either aspirin or an anticoagulant. Aspirin will reduce the stroke risk by around 20%. Anticoagulation will reduce the stroke risk by 60-80% 4 5 . This patient should be offered anticoagulation. Step 1: Review blood results Before offering an anticoagulant, always review the patient’s blood count and creatinine. Use an app such as to calculate the creatinine clearance using the patient’s weight, age, sex and creatinine. Record the creatinine clearance in your notes. Check for anemia which

Full Text available with Trip Pro

2018 CandiEM

9. Sniffer mice discriminate urine odours of patients with bladder cancer: A proof-of-principle study for non-invasive diagnosis of cancer-induced odours (PubMed)

the odour discrimination thresholds of mice in a Y-maze, using urine mixtures from patients with bladder cancer (Stage I) and healthy volunteers (dietary variations) as well as occult blood- or antibiotic drug metabolite-modulated samples. Threshold difference indicated that intensities of urinary olfactory cues increase in the following order: dietary variation < bladder cancer < occult blood < antibiotic drug metabolites. After training with patient urine mixtures, sniffer mice discriminated between (...) urine odours of pre- and post-transurethral resection in individual patients with bladder cancer in an equal-occult blood diluted condition below the detection level of dietary variations, achieving a success rate of 100% (11/11). Furthermore, genetic ablation of all dorsal olfactory receptors elevated the discrimination thresholds of mice by ≥ 105-fold. The marked reduction in discrimination sensitivity indicates an essential role of the dorsal olfactory receptors in the recognition of urinary body

Full Text available with Trip Pro

2017 Scientific reports

10. Faecal Occult Blood Test

Faecal Occult Blood Test Faecal Occult Blood Test and Faecal Immunochemical Test Produced by In partnership with User Top Links Menu Search User Top Links Search Faecal Occult Blood Test and Faecal Immunochemical Test Also Known As FOB, FOBT, gFOBT, Hemoccult, iFOBT, FIT Formal Name Faecal Occult Blood Test This article was last reviewed on 15 September 2015. This article was last modified on 26 January 2019. At a Glance Why Get Tested? To screen for bleeding from the gut/intestine, which may (...) the lab report. For more information on reference ranges, please read . What is being tested? The faecal occult blood test (FOBT) or faecal immunological test (FIT) checks for blood in your faeces. Normally, there will not be enough blood lost through the gastrointestinal tract (stomach and intestines) to turn a FOBT positive or for you to notice it by looking. Any significant amount of blood being passed (seen as bloody or dark, tarry faeces) should be investigated. A positive FOB test will tell your

2012 Lab Tests Online UK

11. Occult hemorrhage in children with severe immune thrombocytopenia. (PubMed)

, urinalysis, fecal occult blood testing, and non-contrast brain MRI. Stool and urine samples were tested within 7 days of diagnosis or symptomatic relapse. Three months after diagnosis or relapse a noncontrast brain MRI evaluated hemosiderin deposits resulting from prior localized hemorrhage. Fifty-two ITP patients were enrolled with a mean platelet count of 4,000/mm(3) . A significant occurrence of occult hemorrhage was identified in the urine (27%) compared with clinically overt hematuria (0.91%, P (...) Occult hemorrhage in children with severe immune thrombocytopenia. Little is known about the frequency and significance of clinically unapparent or occult hemorrhage in ITP. Therefore, we prospectively explored the sites and frequency of occult bleeding in children with severe ITP at diagnosis or upon symptomatic relapse in a prospective, single-institution cohort study of patients ≤ 18 years of age and a platelet count ≤ 10,000/mm(3) . Data collected included bleeding severity assessment

Full Text available with Trip Pro

2015 American journal of hematology

12. Occult Paroxysmal Atrial Fibrillation in Non-Cryptogenic Ischemic Stroke

echocardiogram CT or MR angiography of the head and neck Hypercoagulable blood panel for patients less than 55 years-old. Preliminary hypercoagulable work-up within 7 days will include the antiphospholipid antibody syndrome results, which will be needed to determine stroke management. All other results, which could take longer to return, including genetic tests of hypercoagulability, rarely change stroke management. To find occult PAF in this population, participants will have an insertable cardiac monitor (...) Occult Paroxysmal Atrial Fibrillation in Non-Cryptogenic Ischemic Stroke Occult Paroxysmal Atrial Fibrillation in Non-Cryptogenic Ischemic Stroke - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Occult

2014 Clinical Trials

13. The Efficacy and Safety of the Xue-Fu-Zhu-Yu Capsule in Treatment of Qi Stagnation and Blood Stasis Syndrome.

. The position of pain will be counted independently. Other Outcome Measures: safety outcome [ Time Frame: baseline and 7th week ] physical examination (temperature, respiration, heart rate, blood pressure, height and weight), complete blood cell count, urinalysis, stool examination, fecal occult blood test, liver function (ALT, AST, alkaline phosphatase (ALP), serum total bilirubin (STB), and γ-glutamyl transpeptidase (γ-GT)), renal function (Cr, BUN, and urine N-acetyl-β-glucosaminidase (...) (temperature, respiration, heart rate, blood pressure, height and weight); electrocardiogram (ECG); complete blood cell count; coagulation function (prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT), fibrinogen (FIB), D-Dimer, INR); urinalysis; fecal occult blood test; Liver function (ALT, aspartate aminotransferase (AST), alkaline phosphatase (ALP), serum total bilirubin (STB), and γ-glutamyl transpeptidase (γ-GT)); renal function (Creatinine (Cr), blood urea nitrogen

2017 Clinical Trials

14. A Laser Detection for Bladder Cancer by (Photodynamic) Spectra of Urine

tool for bladder cancer diagnosis only by urine. Research Methodology: The bladder cancer patients is required to swallow a chemical called ALA (5 Amino levulinic Acid hydrochloride), about 10mg/kg body weight which will play a role of biological indicator. ALA gets metabolized into certain types of porphyrins which selectively bind on to the tumor tissues (for a longer time than the normal tissues). 5ml of blood and one urine samples will be taken before using ALA. The patient must drink water (...) laser, of 405nm wavelength. The collimated laser beam falls on the urine sample and excites fluorescence and Raman signals from the porphyrin molecules which have been metabolized from the oral administration of Amino levulinic Acid. Drug: Amino levulinic Acid The bladder cancer patients is required to swallow a chemical called Amino levulinic Acid, about 10mg/kg body weight. 5ml of blood and one urine samples will be taken before using Amino levulinic Acid. The patient must drink water

2014 Clinical Trials

15. Occult hyperparathyroidism and the rapid calcium infusion test (PubMed)

Cortex Hormones Blood Chemical Analysis Calcification, Physiologic Calcitonin Calcium Calcium, Dietary Humans Hyperparathyroidism Parathyroid Hormone Pathology Phosphorus Radiography Sarcoidosis Surgical Procedures, Operative Urine ADRENAL CORTEX HORMONES BLOOD CHEMICAL ANALYSIS CALCIFICATION CALCIUM HYPERPARATHYROIDISM PARATHYROID HORMONE PATHOLOGY PHOSPHORUS RADIOGRAPHY SARCOIDOSIS SURGERY, OPERATIVE THYROCALCITONIN URINE 1964 3 1 1964 3 1 0 1 1964 3 1 0 0 ppublish 14132131 PMC1750525 J Clin Invest (...) Occult hyperparathyroidism and the rapid calcium infusion test 14132131 1996 12 01 2018 12 01 0028-7091 40 1964 Mar Bulletin of the New York Academy of Medicine Bull N Y Acad Med OCCULT HYPERPARATHYROIDISM AND THE RAPID CALCIUM INFUSION TEST. 188-203 CECCARELLI F E FE eng Journal Article United States Bull N Y Acad Med 7505398 0028-7091 0 Adrenal Cortex Hormones 0 Calcium, Dietary 0 Parathyroid Hormone 27YLU75U4W Phosphorus 9007-12-9 Calcitonin SY7Q814VUP Calcium W0CMS474JK elcatonin OM Adrenal

Full Text available with Trip Pro

1964 Bulletin of the New York Academy of Medicine

16. Prevalence of haematuria positively associated with urine albumin excretion in Type 2 diabetes. (PubMed)

2008, patients with Type 2 diabetes at a single centre with data on urinary albumin excretion and urinalysis in the same urine sample were recruited. Urinary albumin excretion was determined by urine albumin/creatinine ratio in spot urine. Diagnosis of haematuria was made by positive urine occult blood from 1+ to 4+ and/or presence of more than nine red blood cells/ml in urinalysis. Demographic, anthropometric, clinical and laboratory variables and diabetes-associated complications were analysed.In (...) Prevalence of haematuria positively associated with urine albumin excretion in Type 2 diabetes. Some guidelines or studies consider haematuria an indication for renal biopsy or a potential cause of albuminuria that precludes accurate assessment of urinary albumin excretion. This study examined the justification of excluding haematuria in interpreting urinary albumin excretion in patients with Type 2 diabetes and its associations with other diabetes-related variables.Between May and November

2012 Diabetic Medicine

17. Urine Metabolomics and Colorectal Cancer Screening

samples will be analyzed for specific metabolites, and establish the metabolomic signature of colorectal cancer. The results from metabolomic urinalysis of this screening cohort will be compared with results from colonoscopy, histological descriptions, fecal occult blood testing (FOBT), and fecal immune testing (FIT) to assess the accuracy of urine metabolomics in identifying patients with polyps and malignancies. The urine metabolomic results from the colorectal cancer group will be correlated (...) Urine Metabolomics and Colorectal Cancer Screening Urine Metabolomics and Colorectal Cancer Screening - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Urine Metabolomics and Colorectal Cancer Screening

2011 Clinical Trials

18. Safety, Blood Levels and Effects of MGB-BP-3

(Part A only), physical examination, laboratory safety tests, faecal occult blood, intestinal permeability (absorptive capacity test using differential sugar absorption with the urine sugars measured using LC-MS, Part B only), faecal flora (Part B only) and Tolerability (AE's & SAE's) Secondary Outcome Measures : To assess the pharmacokinetics (PK) of single and repeated oral doses of MGB-BP-3 in healthy men [ Time Frame: 4 months ] PK parameters of MGB-BP-3 - Composite Metrics Cmax, tmax (...) of blood and urine Willing to use reliable contraception Able to give fully informed written consent Exclusion Criteria: Positive tests for hepatitis B & C Positive tests for HIV Severe adverse reaction to any drug Drug or alcohol abuse Smoke more than 5 cigarettes (or use of equivalent tobacco or nicotine products) daily Received over-the-counter medication within previous 7 days (with the exception of paracetamol) Prescribed medication during previous 28 days Participation in other clinical trials

2015 Clinical Trials

19. Diagnostic utility of rapid immunochromatographic urine antigen testing in suspected pneumococcal infections

methods. Conclusions to be interpreted with caution in view of limited sample size. Esposito et al, 2004, Italy 155 children less than 5 years old with clinically suspected invasive pneumococcal disease. 200 controls without clinical features of infection Case control (level 1c) ICT positivity, blood culture Sensitivity 100%, specificity 80.6%, PPV 14.7%, NPV 100% Positive urine test unhelpful to distinguish true pneumococcal infection from nasopharyngeal colonisation Appropriate study design (...) culture or capsular antigen positivity In group 1, 4 children (26.7%) had positive blood cultures. ICT: Group 1, 86.7% positivity; with increase up to 100% when concentrated urine was used. Group 2, 37.1% positivity; with increase up to 88.2% when concentrated urine was used. Specificity 62.9%; reduction to 11.7% when concentrated urine is used. High sensitivity with a very low specificity. Statistically significant difference between positivity in carriers and non-carriers. Antigen positivity

2008 BestBETS

20. Reproducibility of a Fecal Occult Blood Test Device for Gut Microbiota Analyses

Reproducibility of a Fecal Occult Blood Test Device for Gut Microbiota Analyses Reproducibility of a Fecal Occult Blood Test Device for Gut Microbiota Analyses - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more (...) . Reproducibility of a Fecal Occult Blood Test Device for Gut Microbiota Analyses The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01194687 Recruitment Status : Completed First Posted : September 3, 2010 Last Update Posted : September 18, 2018 Sponsor: National Cancer Institute (NCI) Information provided

2010 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>